CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.865
EU - Europa 5.385
AS - Asia 2.664
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 15
SA - Sud America 15
OC - Oceania 8
Totale 13.967
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.847
CN - Cina 2.200
GB - Regno Unito 2.009
FR - Francia 559
IE - Irlanda 482
IT - Italia 482
SE - Svezia 469
FI - Finlandia 426
RU - Federazione Russa 395
DE - Germania 361
SG - Singapore 312
UA - Ucraina 89
KR - Corea 36
BE - Belgio 30
NL - Olanda 23
IN - India 21
CH - Svizzera 20
TR - Turchia 17
IR - Iran 15
CA - Canada 14
EU - Europa 14
JP - Giappone 14
TG - Togo 11
HK - Hong Kong 10
CL - Cile 7
CZ - Repubblica Ceca 7
PL - Polonia 7
VN - Vietnam 7
AU - Australia 6
AZ - Azerbaigian 5
PH - Filippine 5
ES - Italia 4
LV - Lettonia 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
EC - Ecuador 3
ID - Indonesia 3
LK - Sri Lanka 3
MK - Macedonia 3
AM - Armenia 2
BO - Bolivia 2
CM - Camerun 2
CR - Costa Rica 2
DK - Danimarca 2
EG - Egitto 2
GR - Grecia 2
LU - Lussemburgo 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BR - Brasile 1
CO - Colombia 1
EE - Estonia 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
MX - Messico 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
TH - Thailandia 1
TM - Turkmenistan 1
UZ - Uzbekistan 1
Totale 13.967
Salva come PNG Salva come JPEG
Città #
Southend 1.886
Chandler 1.084
Woodbridge 954
Ann Arbor 620
Dublin 482
Jacksonville 441
Houston 401
Beijing 399
Ashburn 259
Jinan 245
Lawrence 236
Princeton 236
Singapore 213
Wilmington 191
Nanjing 187
Shenyang 154
Hebei 118
New York 100
Tianjin 93
Verona 90
Ningbo 75
Changsha 74
Haikou 70
Helsinki 68
Nanchang 57
Milan 56
Hangzhou 54
Sindelfingen 54
Zhengzhou 54
Jiaxing 48
Taizhou 47
Guangzhou 44
Taiyuan 37
Seoul 36
Seattle 33
Brussels 30
Fuzhou 26
Lanzhou 26
Los Angeles 25
Norwalk 25
Boardman 24
Falls Church 24
Redwood City 24
Dearborn 22
Lancaster 22
Rome 18
Bologna 15
Chicago 13
Dallas 13
Fairfield 13
Kent 13
Redmond 13
Augusta 12
Düsseldorf 11
Lomé 11
Washington 11
Zurich 11
Detroit 9
San Francisco 9
Tokyo 9
Trento 9
Clearwater 8
Munich 7
Zanjan 7
Hong Kong 6
Kochi 6
Mountain View 6
San Mateo 6
Auburn Hills 5
Baku 5
Isola della Scala 5
Markgröningen 5
Santa Clara 5
Amsterdam 4
Ardabil 4
Brescia 4
Brugnera 4
Bussolengo 4
Duncan 4
Fremont 4
Groningen 4
Kemerovo 4
Lille 4
London 4
Monmouth Junction 4
Padova 4
Renton 4
Riva 4
San Diego 4
Tappahannock 4
Toronto 4
Trieste 4
Xiangfen 4
Brno 3
Cambridge 3
Chaoyang 3
Colombo 3
Florence 3
Genoa 3
Henderson 3
Totale 9.806
Salva come PNG Salva come JPEG
Nome #
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 162
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 149
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 136
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 136
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 125
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 122
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 121
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 116
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 113
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 109
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 108
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 107
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 106
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 106
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 105
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 103
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 103
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 102
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 101
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 101
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 100
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 100
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 98
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 98
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 97
Adenocarcinoma of the paraurethral glands: a case report 95
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 95
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 95
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 94
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 94
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 93
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 89
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 89
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 88
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 88
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 87
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 82
Clinical meta-analyses of targeted therapies in adenocarcinoma. 80
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 79
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 78
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 78
The development of PARP as a successful target for cancer therapy 78
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 76
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 75
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 75
Clinical meta-analyses of targeted therapies in adenocarcinoma. 74
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 74
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 74
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 74
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 73
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 73
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 72
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 72
Terapia cronomodulata 71
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 71
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 71
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 70
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 70
Skin Testing and Hypersensitivity Reactions to Oxaliplatin 69
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 69
Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges 67
Comparision of CEA, MCA, CA 15-3 and CA 27-29 in Follow-Up and Monitoring Therapeutic Response in Breast Cancer Patients 67
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 67
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 67
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 66
Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab 66
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 66
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma 65
Antiblastic Chemotherapy in the presence of Abdominal Aorta Aneurysm (AAA): guidelines 65
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 65
2-weekly docetaxel: issues for clinical practice. 65
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 65
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 65
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 65
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 65
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 64
Do immune checkpoint inhibitors need new studies methodology? 64
eComment. Does resected lymph-node number influence survival in non-small cell lung cancer? 63
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 63
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 63
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 63
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 62
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 62
Cardiotoxicity and Incidence Of Brain Metastases After Adjuvant Trastuzumab for Early Breast Cancer: The Dark Side of the Moon? A Meta-Analysis of The Randomized Trials. 61
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 61
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 61
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 60
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 60
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. 60
Physical activity and exercise in lung cancer care: will promises be fulfilled? 60
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 60
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 59
Sorafenib for lung cancer: is the "Battle" still open ? 58
Contralateral Solitary Testis Metastasis Antedating Renal Cell Carcinoma: A Case-Report and Review 58
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 58
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 57
Acute emesis: Moderately emetogenic chemotherapy. 57
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 57
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 57
The obesity paradox in cancer: clinical insights and perspectives 57
Totale 8.100
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.829
article - articoli 52.369
book - libri 343
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.117
Totale 111.658
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.019 0 0 0 57 127 133 169 53 114 88 76 202
2020/20211.525 152 528 56 188 219 136 22 14 15 19 153 23
2021/20221.660 104 543 11 157 43 30 27 99 67 41 136 402
2022/20233.118 270 268 318 585 272 753 32 191 288 19 88 34
2023/20241.541 77 112 118 155 220 225 41 191 32 70 229 71
2024/2025779 234 266 173 106 0 0 0 0 0 0 0 0
Totale 14.203